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Abstract
Engineered nanomaterials (ENMs) are being developed to meet specific application needs in diverse domains across
the engineering and biomedical sciences (e.g. drug delivery). However, accompanying the exciting proliferation of
novel nanomaterials is a challenging race to understand and predict their possibly detrimental effects on human
health and the environment. The eNanoMapper project (www.enanomapper.net) is creating a pan-European
computational infrastructure for toxicological data management for ENMs, based on semantic web standards and
ontologies. Here, we describe the development of the eNanoMapper ontology based on adopting and extending
existing ontologies of relevance for the nanosafety domain. The resulting eNanoMapper ontology is available at http://
purl.enanomapper.net/onto/enanomapper.owl. We aim to make the re-use of external ontology content seamless
and thus we have developed a library to automate the extraction of subsets of ontology content and the assembly of
the subsets into an integrated whole. The library is available (open source) at http://github.com/enanomapper/
slimmer/. Finally, we give a comprehensive survey of the domain content and identify gap areas. ENM safety is at the
boundary between engineering and the life sciences, and at the boundary between molecular granularity and bulk
granularity. This creates challenges for the definition of key entities in the domain, which we also discuss.
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Background
Nanomaterials are materials in which the individual com-
ponents are sized roughly in the 1-100 nanometer range
in at least one dimension, although an exact definition is
still being debated [1,2]. Particles in this size range dis-
play special properties having to do with their very large
ratio of surface area to volume [3]. Natural nanomate-
rials include viral capsids and spider silk. Recent years
have seen an explosion in the development of engineered
nanomaterials (ENMs) aiming to exploit the special prop-
erties of these materials in various domains including
biomedicine (e.g. as vehicles for drug delivery), optics and
electronics [3].
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Counterbalancing the many possible benefits of devel-
oped nanotechnology, nanoparticles also pose serious
risks to human and environmental health [4]. Recognising
these dangers, regulatory bodies are calling for system-
atic and thorough toxicological and safety investigations
into ENMs with the objective of feeding knowledge into
predictive tools which are able to assist researchers in
designing safe nanomaterials. Evaluating and predicting
the possible dangers of different nanomaterials requires
assembling a wealth of information on those materials –
the composition, shape and properties of the individual
nanoparticles, their interactions with biological systems
across different tissues and species, and their diffusion
behaviour into the natural environment. These data are
arising from different disciplines with highly heteroge-
neous requirements, methods, labelling and reporting
practices. Regulatory descriptions of ENMs are not like
those needed for nanoQSAR analyses. Safety require-
ments may also vary under different conditions, e.g. when
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developing vehicles for drug delivery in life-threatening
diseases as compared to materials for use in the construc-
tion industry.
The eNanoMapper project (www.enanomapper.net) is
creating a pan-European computational infrastructure
for toxicological data management for ENMs, based on
semantic web standards and ontologies. eNanoMapper
aims to develop a comprehensive ontology and annotated
database for the nanosafety domain to address the chal-
lenge of supporting the unified annotation of nanomateri-
als and their relevant biological properties, experimental
model systems (e.g. cell lines), conditions, protocols, and
data about their environmental impact. Rather than start-
ing afresh, the developing ontology will build on existing
work, integrating existing ontologies in a flexible pipeline.
The establishment of a universal standardisation schema
and infrastructure for nanomaterials safety assessment
is a key project goal, which will support collaboration,
integrated analysis, and discoveries from data organised
within a knowledge-based framework.
In this paper, we survey the existing ontologies that were
integrated into the unified eNanoMapper ontology, focus-
ing on the challenges we experienced with the integration
of diverse sources and our automated solution for seam-
less modular re-use of external content. Furthermore,
we discuss challenges in the definition of key entities in
the domain and give harmonised definitions for the core
material and experimental entities in the domain.
Problem
The eNanoMapper ontology covers the following broad
content areas:
1. A categorisation of nanoparticle classes based on
their properties, constituency and shape.
2. Physicochemical properties for ENM
characterisation.
3. Biological characterisation that describes the
ENM-specific interactions with, for example,
proteins to form a corona.
4. Environmental characterisation.
5. Experimental design and encoding for experiments
in which nanosafety is assessed.
6. The full nanomaterial lifecycle including
manufacturing and environmental decay or
accumulation.
7. Known safety information about ENMs.
Table 1 gives a summary of the ontologies that have been
identified as already in part covering these domain areas.
The selection of ontologies is motivated by the require-
ment that the ontologies be (a) open, that is, licensed for
re-use without restriction other than attribution, (b) suit-
able for use in data annotation, i.e. using unique numeric
identifiers and offering textual labels and definitions, and
(c) be broadly mutually compatible (although with some
provisos as we will discuss in the section on our re-use
pipeline below).
These ontologies are described further in the Results
section below. However, our initial “naïve” attempt to re-
use these ontologies in their entirety in the development
of the integrated eNanoMapper ontology ran into several
challenges:
• Some content was duplicated across multiple
different ontologies, resulting in multiple classes with
different identifiers being included with the same
label – including cases where classes with the same
label were defined differently across the ontologies;
• Some classes which were multiply imported, i.e.
following the recommended re-use policy, in the
ontologies we imported, such as frequently used
upper-level classes or unit classes, subsequently were
found to have multiple copies of all associated
annotations and axioms in the resulting composite
ontology;
• It was difficult to reconcile the different upper level
ontologies that were used in these ontologies, and in
some cases even when the same upper level ontology
was used (BFO), different versions of that upper level
still caused incompatibilities;
• The presence of gaps in the imported content
necessitates the manual annotation of content
additions (which may later be submitted to various
source ontologies). It was not easy to seamlessly add
manual content to the imported ontologies without
needing to re-create the manual content every time
the source ontologies changed and were re-imported;
and
• Some of the definitions of the classes we wanted
to re-use were missing or not sufficiently clear
for unambiguous re-use as part of an integrated
whole.
Based on exact label matching only, the overlap between
the ChEBI ontology and theNPO is 395. This is a small but
nevertheless significant number of exactly shared labels.
Most of these are groups, atoms or chemical classes that
are included in NPO so as to support description of nano-
material composition. Some, but not all, of these are cross-
referenced to ChEBI via an additional annotation ‘dbXref ’
in NPO. Other classes with overlapping labels derive from
the fledgling nanoparticle classification that is included
in ChEBI. For this branch of NPO, there are no cross-
references annotated to ChEBI (and neither does ChEBI
annotate cross-references to NPO). Some of the overlap
arises from drug classes that are included in the NPO,
e.g. thalidomide and tamoxifen, assumedly because the
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Table 1 A summary of the ontologies that have been identified as covering content areas of relevance for eNanoMapper
Ontology detail Availability Primary content and focus
NanoParticle Ontology (NPO), [5] http://bioportal.bioontology.org/ontologies/NPO Nanomaterial types, properties and
experiments
Chemical Entities of Biological Interest (ChEBI), [6] http://www.ebi.ac.uk/chebi/ Chemical compounds, groups and
roles, and nanomaterial types
Chemical information ontology (CHEMINF), [7] http://code.google.com/p/semanticchemistry/ Chemical qualities and descriptors,
both calculated and measured
Chemical Methods Ontology (CHMO) http://purl.bioontology.org/ontology/CHMO Chemical processes and
experimental methods
Physico-Chemical Process Ontology (REX) http://www.obofoundry.org/cgi-bin/detail.cgi?id=rex Chemical processes and
experimental methods
Unit Ontology (UO), [8] http://code.google.com/p/unit-ontology/ Units for measured or calculated
quantities
Phenotype and Quality Ontology (PATO), [9] https://code.google.com/p/pato/ Qualities and phenotypes
Ontology for Biomedical Investigations (OBI), [10] http://obi-ontology.org/ Experiments and assays
BioAssay Ontology (BAO), [11] http://bioassayontology.org/ Experiments and assays
Gene Ontology (GO), [12] http://amigo.geneontology.org/ Molecular functions, biological
processes and cellular components
Protein Ontology (PRO), [13] http://pir.georgetown.edu/pro/pro.shtml Proteins and protein complexes
Cell Ontology (CL), [14] https://code.google.com/p/cell-ontology/ Cell types
Cell Culture Ontology (CCONT), [15] http://purl.bioontology.org/ontology/CCONT Cell lines
UBERON, [16] http://uberon.org Multi-species anatomy
Environment Ontology (ENVO), [17] http://purl.bioontology.org/ontology/ENVO Environments such as soil and
sediment
Ontology of Adverse Events (OAE), [18] http://purl.bioontology.org/ontology/OAE Adverse events of a medical nature
NPO was designed for cancer nanotechnology research
and these are cancer drugs.
The OBO Foundry recommends collaboration to
resolve overlap between neighbouring ontologies in situa-
tions such as these. A strategy that suggests always favour-
ing one ontology over another is not possible, since for
groups and chemical classes the ChEBI IDs are preferred,
while for nanoparticle classes it is the NPO IDs.
Between BAO and NPO there are 37 overlapping labels.
These include abstract classes such as ‘physical quality’,
‘shape’, ‘size’; and role classes such as ‘solvent’, ‘dihydro-
folate reductase inhibitor’ and ‘fluorochrome’. Note that
label sharing in itself is not a problem unless the IDs are
different. If the MIREOT strategy is followed [19], the IDs
and definitions will be exactly the same, which presents
no problem for data annotation. This is the case for the
bulk of the overlap between BAO and ChEBI, which with
696 shared labels would otherwise be very challenging to
resolve.
Thus, in order to create a seamless and unified whole
ontology, rather than importing the external ontologies in
full we decided to create a pipeline for ontology re-use that
enabled the import of parts of the external content, assem-
bly of those parts beneath a slim upper level, and the use of
those parts together with manually added content in a way
that would be unaffected by regular updates of the source
ontologies. This pipeline needed to be able to fit together
imported ‘branches’, ‘leaves’ or diverse parts of external
ontologies, and branches of manually annotated content,
like jigsaw pieces together into a unified whole. Our strat-
egy for managing duplication in the combined ontology
resource is to systematically prune (i.e. remove) dupli-
cated content as part of the import process for ontologies
that are re-used. In each case, a primary provider for the
content domain is selected. For example, for nanoparticle
classification it is the NPO, for small molecules such as
drugs it is ChEBI, for biological assays it is OBI etc. Dupli-
cated content in other ontologies that are imported are
then removed automatically by our pipeline.
In the next section we describe the pipeline we have cre-
ated for this purpose and the way we have applied it to
build up the eNanoMapper ontology from the component
ontologies.
Results
The eNanoMapper ontology is being developed in the
Web Ontology Language (OWL), Version 2 [20]. One of
the primary requirements on the source ontologies we
chose to adopt is that they are available in OWL. How-
ever, as described above, in most cases we do not want
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to import the full external ontology. This may be because
we only require a portion of the content, or because we
need to exclude content that has already been imported
from elsewhere thus would cause a duplicate if imported.
A particularly challenging form of duplicated content
for a complex application ontology such as eNanoMap-
per arises from multiply chained imports. When OWL
imports the same content (e.g. ChEBI together with the
portion of ChEBI that is already imported into the NPO),
any associated metadata and axioms are duplicated. Thus,
for core ontologies such as BFO that are imported by
multiple other ontologies, the metadata are duplicated
multiple times. This is expected behaviour in the con-
text of OWL but presents a problem for complex import
chains of ontologies as is needed for eNanoMapper.
For these reasons, we have created an ontology ‘slim-
ming’ library which extracts subsets from existing ontolo-
gies according to predefined criteria. Subsets are then
placed in a special folder (/external/) in the ontology
development area, which is located on GitHub at http://
github.com/enanomapper/ontologies. The subsetsmay be
created through the identification of classes to extract,
with the option to include their parents (paths to root)
and/or children (paths to the leaves). Specific metadata
and axioms may be identified for inclusion or exclusion.
By default, all classes in the source ontology are excluded.
We are using Jenkins as a platform, similarly to the
pipeline described in Mungall et al. [21], to enable contin-
uous integration with logical consistency and coherence
testing so as to ensure that the incorporation of updates
from source ontologies does not lead to fragmentation
and inconsistencies in the integrated whole. Our continu-
ous build system is publicly available online at http://jenm.
bigcat.maastrichtuniversity.nl/. We are performing mul-
tiple quality control tests on a regular basis in addition
to the composite ontology consistency check, including
checking for the presence of labels and definitions across
all classes included in the resource.
The code to do the slimming uses the OWLAPI
library [22]. There are configuration files to specify the
required information and the instructions for how the
slimming should be performed (see https://github.com/
enanomapper/slimmer/). For each imported ontology, a
Java Properties file defines the input ontology, where the
slimming instructions (i.e. what to include or exclude) can
be found, and the IRI for the resulting slimmed OWL file.
The slim files are created with ontology IRIs within the
http://purl.enanomapper.net domain which was specifi-
cally set up for our ontology work. The IRIs for classes and
properties are maintained as they are in the original input
ontology. The pipeline operates as illustrated in Figure 1.
Firstly, the slimmer takes the configuration files, loads
the primary ontology and merges it with the imported
ontologies. This is to ensure that any class defined in any
downstream imported ontology can also be exported into
the slimmed ontology. During this process, all annotations
on the ontology are maintained; these are complemented
with annotation detailing the eNanoMapper project as
publisher of this slimmed version of the source ontology,
when the integrated ontology was made, and informa-
tion about the tools used. The slimmer then removes all
classes aside from those specifically listed for inclusion in
the slimming instructions. The slimming instructions are
defined in a separate file with a custom, dedicated format.
Each line specifies an IRI of a class to keep, or to remove
from a kept branch. For each IRI it is possible to further
specify either that the chain of superclasses for that class,
or all subclasses (i.e. a downward branch) should also
be kept. This enables the selection of whole subtrees for
inclusion, while still allowing for the possibility of prun-
ing out components of the sub-tree individually. To ensure
that the resulting slimmed files will arrange themselves
hierarchically when used together in the composite whole,
for each instruction it is possible to specify a superclass
for the class with the given IRI, which superclass does not
have to be defined in the ontology processed, i.e. this facil-
ity can link imported branches to components from other
ontologies. Optionally, the line then terminates with a
free-text comment which can be used to assist the human
maintainers of the file, as the ontologies we have adopted
do not use human-readable IRIs.




This instruction says that the class UO_0000000 (unit)
should be included from the unit ontology together with
all its descendents, and that this class should be defined as
a subclass of IAO_0000030 (information content entity),
which in turn will be imported directly from IAO. The
label of the class to be extracted is included only for
human readability. While it is not necessary to specify
a superclass for each IRI included in the instructions,
it enables “cross-linking” imported classes or subsets to
the remainder of the content in the assembled ontology
without having to do repetitive manual work in order
to stay up-to-date with the source ontologies as they
evolve.
Using this slimming library we are able to build up our
ontology from components drawn from existing ontolo-
gies. All of the generated slimmed ontologies are sub-
sequently imported into a single OWL file, http://purl.
enanomapper.net/onto/enanomapper-auto.owl which is
in turn then combined with manually curated enanomap-
per content in the final ontology file http://purl.
enanomapper.net/onto/enanomapper.owl.
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Figure 1 The operation of the slimming procedure.
In the next sections we describe which components we
have selected from which external ontologies and how
they have been interweaved.
Nanoparticle types
Nanoparticles are typically classified primarily on the
basis of their primary constituent, e.g. silica, carbon, tita-
nium dioxide, gold or silver, nanoclay, etc., and their
shape. The primary ontology relevant for nanoparticle
types is the NPO. It was created out of the need to
standardise data description in cancer nanotechnology
research and enable searching and integration of diverse
experimental reports. The NPO uses the Basic Formal
Ontology (BFO, [23]) as upper level and is developed in
the Web Ontology Language (OWL). It refers to multiple
external ontologies including ChEBI. As of the last release
(2011-12-08), the NPO contains 1,904 classes.
It includes the type of chemical components of a
nanoparticle formulation which include the nanoparti-
cle, active chemical constituents of the nanoparticle, and
functionalizing components. The molecular structure of
the chemical components is also included (e.g., atom, ele-
ment, compound, liposome, micelle, etc.) – in some cases
these have been imported from ChEBI.
ChEBI is both a chemical database and a chemical
ontology. It offers a wide range of useful chemical infor-
mation including chemical structures and properties, cita-
tions to the literature and both a structure-based and a
role (activity)-based ontology classification. As of the last
release (1 January 2015) there are 42,318 classes in ChEBI.
The bulk of the chemicals annotated in ChEBI are organic
molecular entities of biological interest as metabolites or
agents that can intervene in biological processes. The
most relevant for the eNanoMapper project are the func-
tional groups and atoms which are used to describe the
composition and functionalisation of nanoparticles.
The NPO contains an extensive classification of types
of nanoparticle based on structure, function or chemi-
cal composition (e.g. ‘chitosan nanoparticle’ (NPO:261),
‘spherical nanoparticle’ (NPO:1551), ‘gold nanoparticle’
(NPO:401), ‘core-shell silica nanoparticle’ (NPO:1572),
‘fluorescent silica nanoparticle’ (NPO:1553) and ‘long cir-
culating nanoparticle’ (NPO:1591)). ChEBI also contains
a small ‘chemical substance’ branch with a small nanopar-
ticle classification, primarily around types of nanoparticle
based on their chemical constitution, some of which do
not also appear in the NPO (thus are not superfluous).
For example, ChEBI contains ‘palladium-gold nanoparti-
cle’ (CHEBI:52523) which is defined as a gold nanoparticle
covered with a thin coat of palladium atoms, and also
‘citrate-coated silver nanoparticle’ (CHEBI:82778).
We have imported both the nanoparticle classification
from the NPO and from ChEBI, but for ChEBI we have
removed those classes which duplicate classes in NPO.
Nanoparticles may be simple (e.g. nanodot with a par-
ticular composition) or complex, in that they may be
composed of several layers and their surfaces may be het-
erogeneously functionalised with attached groups of any
composition. We have imported from the NPO a few gen-
eral classes for these complex particle types including ‘sur-
face functionalized nanoparticle’ (NPO:1881); however,
more specific detailed classes of types of functionalisa-
tion are not yet present. The molecular composition of
the nanoparticle includes a specification of the constituent
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groups and atoms together with their bonding arrange-
ment. When describing the molecular composition of
nanoparticles it may be necessary to distinguish the
molecular composition of specific parts of the nanoparti-
cle, e.g. the surface, core, linkage etc. The NPO includes
classes for the different parts of the nanoparticle e.g. ‘silica
core’ (NPO:1865), and chemical linkages between chem-
ical components (e.g., amide linkage, disulfide linkage,
encapsulation) and the physical, chemical, or functional
properties of chemical constituents and functionalizing
agents (e.g., organic, hydrophilic, magnetic, etc.).
Nanoparticles are also commonly described by their
dimensionality and shape. These aspects are partly
covered by NPO. ‘Dimensionality’ describes the num-
ber of dimensions of the particle that are within the
‘nanoscale’ (i.e. between 1 and 100 nm). Thus quan-
tum dots, hollow spheres and free nanoparticles, in
which all three dimensions are in the nanoscale, are
described as three-dimensional (some sources use the
term ‘zero-dimensional’). Analogously, nanorods, nan-
otubes, nanowires and nanofibres, which have two dimen-
sions in the nanoscale, are known as two-dimensional,
while thin films or surface coatings, which have only
one dimension in the nanoscale, are classed as one-
dimensional. Nanoparticles come in different shapes,
providing another useful descriptor for classification pur-
poses. Thus two-dimensional nanoparticles may occur as
rods, helices, zig-zags, or belts, whilst three-dimensional
nanoparticles may be conical, cylindrical, ellipsoidal, ellip-
tical, polyhedral, spherical, etc. Both the dimensionality
and the shape of nanoparticles can be important factors
in determining the toxicity of nanoparticles, their cellular
uptake etc. In addition, nanoparticles have other relevant
material or mechanical properties such as being soft or
hard (stiff ). The majority of these properties have been
imported from NPO.
The NPO also contains items of relevance for bulk
nanomaterial description, such as the physical state of a
formulation (e.g., emulsion, hydrogel, etc.).
ENM physico-chemical characterisation
The sorts of physicochemical properties that are used in
the characterisation of nanomaterials include the state of
dispersion, aggregation and agglomeration of the nano-
material, the size (and size distribution) of the particle, the
specific surface area and porosity, the surface composition
and reactivity (a measure of the extent to which the sur-
face atoms of the nanomaterial can induce the production
of reactive oxygen species), and the purity (and impuri-
ties). Impurities can play a crucial role in determining the
safety or toxicity of nanomaterials, so should be quantified
and described.
The materials, rather than the particles, are described
by the particle size distribution and the remainder of the
medium in which the particles are contained, including
solubility and dispersability in different media including
water. Zeta potential is especially important to predicting
the aggregation and agglomeration behavior of particles,
and may be measured over a pH range. Diffusion and
gravimetric deposition rates should be characterised, as
they affect the dispersal and exposure time for substances
leaking into the environment.
CHEMINF is an ontology of chemical information enti-
ties - descriptors and other chemically relevant data items,
designed to support data sharing and standardisation of
cheminformatics data in the context of the SemanticWeb.
As of the last release (5 December 2014), the ontology
contains 732 classes. CHEMINF is already the standard
for chemical property representation in Open PHACTS
[24], and we have contributed a set of nanomaterial-
relevant descriptors to it. Many cheminformatics descrip-
tors included in CHEMINF, such as molecular mass,
pKa and so on, are straightforwardly relevant also to
data about nanomaterials, and we have imported the full
branch of chemical descriptors into eNanoMapper from
CHEMINF.
While not an ontology, the OECD Harmonized Tem-
plates are structured (XML) data formats for reporting
safety-related studies [25] that contain vocabularies in the
form of picklists for some of the specified fields, and doc-
umented guidance material. There are several templates
that are specific to nanomaterial assessment over and
above the templates that apply to all chemicals. These fall
under the header “additional physico-chemical properties
of nanomaterials" and include agglomeration/aggregation,
crystalline phase, aspect ratio/shape, dustiness, porosity,
pour density and radical formation potential. These terms,
where not already present in NPO or CHEMINF, have
been manually annotated in eNanoMapper.
Biological characterisation
Through interactions with biological systems, nanoparti-
cles may become covered with biological material, partic-
ularly proteins in the blood, and lipids in the pulmonary
system. This is referred to as the “corona” of the nanopar-
ticle and it strongly depends on the exposure medium
(e.g. bovine serum) and the duration of exposure [26,27].
The corona may be composed of a monolayer or mul-
tiple layers, and the proteins may be denatured by their
adsorption to the nanoparticle, creating entirely novel
biomolecular entities with unknown reactivities. Simi-
larly to protein-protein interactions, nanoparticle-protein
interactions are characterised by binding affinity, stoi-
chiometry, and kinetic properties.
The corona affects biodistribution and cellular uptake
of the nanoparticle and may also cause some toxic effects.
In short, exposure to any biological medium changes the
external nature of the nanoparticle and thus its biological
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effects [28]. It is therefore very important that all data
points include metadata to describe the history of each
sample and to control carefully for exposure to biological
material.
In addition to proteins, nanoparticles can also bind to
and interact with DNA, or interact with whole cells [29].
Cell association (i.e. binding and uptake to cells of a given
type) is a measurement of special importance for its rel-
evance to inflammatory responses, biodistribution, and
toxicity in vivo [27].
Foremost among the existing biological ontologies is the
GO, the widely used ontologies for biological processes,
molecular functions and cellular components used in gene
product annotation. GO is the gold standard for annota-
tion in these three sub-domain areas. It contains 42,329
classes (as of 22 December 2014).
For annotation of proteins, PRO may be used. With
83,656 classes (12 June 2014), it contains species-neutral
grouping classes for all proteins identified in UniProt as
well as links to the species-specific UniProt entries.
For annotation of cellular entities, the Cell (CL) ontol-
ogy may be used (6,287 classes as of the 22 December
2014 release). The Cell Culture Ontology is also relevant
(CCONT).
Importing biological entities from external ontologies is
common practice in assay-related ontologies. For exam-
ple, BAO has a good selection of imported biological
entities for use in annotation of assays against biological
endpoints.
The NPO also includes content of relevance for the
biological characterisation of nanoparticles, including the
underlyingmechanisms guiding the design for a particular
formulation (e.g., endocytosis, active targeting, etc.), types
of stimuli (e.g., magnetic field, ultrasound, pH change,
etc.) for activating the function of nanoparticles, and
the responses to those stimuli (e.g., drug release from
nanoparticle in response to magnetic field, heat genera-
tion from nanoparticle in response to infrared light, etc.),
the biochemical roles or functions of included chemi-
cal components (e.g., anticancer drug, surface modifying
agent, MRI contrast agent, spacer, etc.) and applications
of nanomaterials especially in cancer diagnosis, therapy,
and treatment (e.g., chemotherapy, diagnostic imaging,
detection of cancer cells, etc.).
Environmental characterisation
Nanoparticles may be released into the environment
throughout their lifecycle, including their initial synthe-
sis, incorporation into a product, use by consumers, and
disposal, so subjecting workers, consumers and the envi-
ronment to potential exposure. A variety of methods and
measurements may be used in order to assess exposure,
including the use of particle number, particle mass, and
surface area detection devices.
When describing the environmental hazards and assess-
ments of the environmental impact of nanomaterials,
once they get ‘into the wild’, it will also be necessary to
refer to a wide range of different ecosystems, environment
types and locations.
ENVO contains terminology covering a wide range of
environments including, for example, marine zones, tidal
zones, soil and so on (1,691 classes as of the 17 September
2014 release). It also contains biomes such as desert and
grassland; environmental features such as archaeological
sites, caves and beaches; and environmental conditions
such as arid and subtropical.
Experimental measurements and protocols
In addition to the variousmeasurement outcomes (physic-
ochemical and biological characterisation and prop-
erties) discussed above, measurement techniques and
tools are included in the eNanoMapper ontology. These
include [30]:
• Transmission electron microscopy, scanning
electron microscopy and atomic force microscopy
provide information about the nanoparticle
morphology.
• Crystallographic methods can be used to determine
the shapes of particles.
• Dynamic light scattering (DLS) provides information
on the hydrodynamic radii of nanoparticles in
solution.
• Surface charge properties are determined with
zeta-potential measurements.
• Chemical composition is revealed by auger electron
spectroscopy, x-ray photoelectron spectroscopy,
time-of-flight mass spectrometry and elemental
analyses.
• Surface ligands and adsorbed molecules are identified
with magic angle spinning nuclear magnetic
resonance, liquid chromatography mass spectroscopy
(LC-MS) and Fourier-transform infrared
spectroscopy. Surface-enhanced Raman spectroscopy
may also be used.
• Size exclusion or thin layer chromatography can
identify nanoparticle-bound lipid molecules.
• Binding of surfactant molecules onto the surfaces of
nanoparticles may alter their surface plasma
resonance absorption and can also be determined
using UV-vis absorption spectroscopy.
• Surface pressure-area isotherm measurements can be
used to study the properties of lipid monolayers in
the presence of nanoparticles.
• Differential scanning calorimetry (DSC) and
isothermal titration calorimetry (ITC) can be used to
measure thermodynamic changes in supported
membranes or liposomes.
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• Steady-state and time-resolved fluorescence
spectroscopy are used to study nanoparticle-protein
binding affinities, complex formation, and
binding-induced protein conformational changes.
• Stepwise photobleaching has also been used to
characterize nanoparticle-protein interactions.
• Proteins bound to a nanoparticle surface may be
identified by 2D polyacrylamide gel electrophoresis.
• The adsorption and desorption processes of
nanoparticle-DNA complexes can be measured using
cyclic voltammetry.
• Cellular uptake can be monitored using X-ray
fluorescence microscopy to determine the chemical
element distribution of nanoparticles in cells.
• Magneto-photoacoustic imaging can be used to
differentiate membrane-adhered from endocytosed
nanoparticles in a cell.
• Atomic force microscopy measures the force between
nanoparticles and the cell surface in cell association.
The details of the experimental methods captured in
an ontology may include links to instruments used in the
measurements. The NPO contains experiment types of
relevance in nanomaterial characterisation, e.g. ‘dynamic
light scattering’; and experimental methods for synthe-
sis, e.g. ‘solvent displacement method’. More experimental
types of relevance for physicochemical characterisation
are also included in CHMO and REX.
ISA-TAB is a commonly used format for representing
experimental data in structured tab-separated files [31].
There are three file types: investigation, study and assay.
The investigation file contains the broad reference infor-
mation about the project in the context of which the bio-
logical experiment has been performed, such as the point
of contact and publications, and includes reference details
for the other files. The study file includes all the informa-
tion about the sample being tested, and the investigation
file records the raw data of the assay (or specifies the files
for the raw data for non-spreadsheet, e.g. image data). The
ISA-TAB Nano specification enhances the “pure” ISA-
TAB specification with support, in the form of an addi-
tional file type “material”, for describing nanomaterials
[32]. While the study file enables description of samples
of biological origin, the material file enables description
of samples of non-biological origin, whether nanoscale or
not. It enables the description of complex nanomaterial
formulations including chemical components, functional-
izing agents, and medium of suspension.
There are at least two ontologies in the biomedical
domain that include biological assay descriptions: OBI
and BAO. While OBI is broader in scope and has the
involvement of many different communities in its devel-
opment, BAO has arisen from a more specific targeted
need in chemical biology data annotation. OBI has 2,799
classes as of the last release (17 December 2014) and BAO
has 3,340 (11 November 2014). As will be discussed fur-
ther below, OBI is more metadata-rich than BAO, while
BAO has a neater classification hierarchy. OBI also has a
wider diversity of assays represented. However, their con-
tent is not fully overlapping and both are relevant (thus we
have imported assays from both). Neither OBI nor BAO
have any nanomaterial-specific content or assay types.
The explicit and detailed protocols for all assays and
measurements should ideally be captured in ontology
annotations in just as much detail as they are described
in the experimental methods sections of high-quality
publications, i.e. in sufficient detail to allow them to be
reproduced. The ontology, however, can only supply the
vocabulary to be used in such descriptions. The enforce-
ment of the minimum level of detail required when anno-
tating data of a given type (about a particular experiment)
needs to be done via alternative methods combined with
the use of the ontology as knowledgebase and vocabulary.
For example, experimental templates such as the OECD
Harmonized Templates can suggest which fields need to
be filled for various different types of experiment, and
Minimum Information guidelines could be created to use
as checklists for automatic quality-checking of data. Core
content checklists such as the OECD HTs have previ-
ously been formalised for this purpose in the context of
theOpenTox project [33,34]. To this end, in addition to the
dedicated annotation of assays captured in ontologies, the
PROV-O ontology (a W3C recommendation, [35]) pro-
vides many useful classes and relationships for expressing
provenance information associated with data, which can
include who generated it, when, what it is derived from,
and what software was used in the production.
Nanomaterial lifecycle
The full ‘cradle to grave’ nanomaterial lifecycle from syn-
thesis through use to recycling, disintegration or envi-
ronmental accumulation needs to be described in the
ontology.
While coverage of this aspect of nanomaterials is poor
in existing ontologies, the NPO contains a few relevant
classes, including ‘biodegradable nanoparticle’ (NPO:836)
as a class of nanoparticle type. The definition in NPO
refers to the property (quality) of being ‘biodegrad-
able’ (NPO:191). NPO also contains a small number of
manufacturing-relevant classes under ‘material synthesis
technique’ (NPO:1921).
For nanomaterial manufacturing, the InterNano
Nano-Manufacturing Taxonomy provides vocabulary,
using numeric identifiers. It is available at http://purl.
bioontology.org/ontology/InterNano. It includes bran-
ches such as application areas for nanotechnology, health
and safety, nanomanufacturing and characterisation
processes, a classification of nanomaterial types, and
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social and economic impacts. The taxonomy is used
for intelligent searching and to organize content on the
internano.org website. While a very useful resource in
terms of terminology, the taxonomy does not include
additional metadata, such as synonyms or definitions. It
also does not include further ontological content such as
relationships (other than hierarchy).
Known safety information
The ontology should support the rapid retrieval of rele-
vant safety information given a particular class of ENMs
and a particular biological context. While the safety data
itself will be included in the eNanoMapper database (not
the ontology), the ontology needs to include classes for
different types of toxicological endpoints as well as the
experiments that are conducted to evaluate and assess
toxicity in different systems.
Regulatory language used to describe safety hazard
classes is also required in the context of the ontology, to
enable organising and searching the known information
from the literature.
In order to describe safety outcomes in medical con-
texts we have incorporated the classification of adverse
events from the Ontology of Adverse Events (OAE, [18])
which comprehensively annotates adverse events or reac-
tions of medical relevance. An example of an adverse
event from this ontology is ‘hypertension adverse event’
(OAE_0000403).
Summary
The different components that have been discussed above
have been integrated into a composite ontology in which
the original IRIs and hierarchical structure for the sub-
sets which are imported are maintained, but the way they
are assembled together is through specifying new parents
for imported subset modules such that they automatically
fit together. A subset of the resulting ontology is illus-
trated in Figure 2, with an emphasis on how the slimline
upper level (a subset of BFO) is used to ‘glue’ together
the different parts of the external ontologies in a coherent
fashion. Some ontologies have components which form
subsets in multiple different basic types (such as the NPO,
BAO), while others mainly contribute their content to one
branch or to one main content type. Our manually anno-
tated content can also be observed in multiple different
branches (tagged as ENM), extending classes imported
from elsewhere.
As part of the overall eNanoMapper project, a database
is being developed in which the content will be richly
annotated with ontology IDs [36]. To assist researchers
in providing such annotations, an ontology annotation
recommendation tool is being developed that wraps the
NCBO annotation recommendation service [37] in the R
language (https://github.com/muntisa/RNCBO). It takes
as input a list of terms needing annotations, and as output
suggests possible annotation values based on the lookup
across the BioPortal collection [38]. The challenges with
overlaps and gaps in content described here also apply to
this tool as long as it harnesses existing publicly available
content. In the future, this recommendation tool will be
extended to offer a version that has been restricted to the




Each of the ontologies mentioned in the above con-
tent areas provides partial to good coverage of their
specific domain areas. However, the composite suite
of external ontologies nevertheless does not cover the
full domain of nanosafety as needed for eNanoMapper.
Further experiments need to be annotated, particularly
toxicology and nanomaterial-specific experiments, and
nanomaterial-specific properties need to be added to var-
ious ontologies. Even dedicated ontologies such as the
NPO need to be updated in the light of recent advances
in the field of nanotechnology safety, including a growing
diversity of novel nanomaterial types and new approaches
to describing biological interactions.
In an effort to concretely evaluate the coverage of the
ontologies against the terminological annotation require-
ments arising from public data, we used two targeted
data annotation terminology sets. These were the char-
acterisation properties described in the “protein corona”
dataset (the data from [39]) in the eNanoMapper pro-
totype database ([36]) and the terminology used in the
OECD Harmonized Templates specific to nanomaterial
characterisation.
From the protein corona dataset characterisation prop-
erties, of 21 properties reported 12 had exact matches
within the external ontologies being imported, while
an additional five had close matches where a compos-
ite annotation would serve the purpose. Examples of
terms that had exact matches include DLS (NPO_1469),
polydispersity index (NPO_1155) and g/cm3 (NPO_1270,
UO:0000084). Partial matches include ‘z-average hydrody-
namic diameter’ which can be annotated with a composite
of NPO_1916 (z-average) and NPO_1915 (hydrodynamic
diameter). Of the terms that had no match at all included
‘per NP’ units such as cm2/NP. These are nanomaterial-
specific units that are in scope for submission to the
NPO.
Of the 26 terms in the OECD HTs dedicated to nano-
material characterisation, six had no exact match in the
imported ontology suite, including ‘dustiness’, a property
that can be defined as the propensity of a powder to
become aerosolised by mechanical agitation, dependent
on its moisture content and static electrical properties
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Figure 2 An overview of the upper levels and integration of external ontology content together with manually annotated (ENM) content.
[40], ‘pour density’, and ‘crystallite and grain size’. We
have annotated these in the manual eNanoMapper con-
tent, and they are within scope for, thus will be submitted
to, the NPO. There were also many terms in the OECD
HTs that were not specific to nanomaterials but rather
to evaluations of the safety of any chemical, which were
missing from our suite of imported ontologies. These
include classes for biodegradation under different circum-
stances, e.g. ‘biodegradation in water’, ‘biodegradation in
soil’, and ‘bioaccumulation’. It also includes many differ-
ent toxicity classes such as ‘short-term toxicity to fish’,
‘acute toxicity - inhalation’ and ‘teratogenicity’. Some of
these toxicity classes are present in the OpenTox endpoint
ontology that was developed in the context of the Open-
Tox project. However, this ontology is not interoperable
with the remainder of the ontologies in the suite as it does
not use numeric identifiers complemented with textual
labels and definitions. Thus, the content of the OpenTox
endpoints ontology as well as the other toxicology-related
terms not yet included have been added to an endpoints
branch of the eNanoMapper ontology manually curated
content as subclasses of BAO’s endpoint class, http://purl.
enanomapper.net/onto/internal/endpoints.owl.
In general, nanotechnology-specific assays, properties
and related materials are sparsely represented in existing
ontologies and thus need to be added to the existing assay
and chemical information ontologies. In order to be of the
widest possible benefit, the eNanoMapper project envi-
sions submitting relevant terminology to targeted external
ontologies for inclusion at the source rather than append-
ing content in the eNanoMapper ontology only. Much
of the missing content that we have identified so far is
in scope for one of the ontologies already targeted for
import, e.g. the NPO, BAO or OBI, CHEMINF, ChEBI or
CHMO.
Several of the content areas that are relevant for nano-
material safety assessment are thus far not covered by any
existing publicly available ontology, thus will need to be
manually annotated into eNanoMapper. One such gap is
the nanomaterial lifecycle, from manufacturing through
to environmental and biological impact. These toxicology
and safety-related terminology areas present a gap which
is not presently covered by an ontology that conforms
to the OBO Foundry [41] recommendations for inter-
operable ontologies. The InterNano Nanomanufacturing
Taxonomy forms a good starting point for terminology in
this area, but that terminology needs to be defined and
further annotated. Known safety information is another
gap. Database efforts such as the OECD Database on
Research into the safety of manufactured nanomaterials
may serve as a starting point for this.
Harmonizing definitions
Ontologies contain additional information relative to the
labels and identifiers that are so useful for annota-
tion. They contain definitions, relationships and complex
axiomatisations in terms of those relationships. The NPO
already contains a sophisticated axiomatisation for some
parts of the ontology, embedding detailed domain knowl-
edge of relevance for nanomaterial research into logical
definitions captured in the ontology. This is described in
detail in [5].
For example:
• the class ‘intracellular fluid in a tumor cell’ is defined
as “ ‘intracellular fluid’ and (contained_in some
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‘intracellular space of tumor cell’) and (has_quality
some ‘tumor intracellular pH’)”;
• the class ‘carbohydrate-coated nanoparticle’ is
defined as “nanoparticle and (has_component_part
some (carbohydrate and (has_role some
“nanoparticle surface modifying role’)))”;
• the class ‘fluorescence imaging contrast agent’ is
defined as “ ‘optical imaging contrast agent’ and
(has_application some ‘fluorescence imaging’) and
(has_property some fluorescent)”;
• the class ‘elimination rate constant’ is linked to the
class ‘pharmacokinetics study’ using the relationship
‘parameter determined from’.
However, such axiomatisations can differ remarkably
from ontology to ontology, a fact not always highlighted in
a straightforward overlap analysis. For example, the def-
initions for the assay classes in OBI and BAO are very
different. OBI defines ‘assay’ as
“A planned process with the objective to produce
information about the material entity that is the
evaluant, by physically examining it or its proxies.”
BAO, on the other hand, does not include ‘assay’ as a
term, it includes ‘bioassay’, defined as
“A set of instructions, methodology, operations,
required reagents, instruments to carrie out
experiments for the purpose of testing the effect of a
perturbing agent in a biological model system,
measuring one or multiple effect(s) of the agent
facilitated by an assay design method translate the
perturbation into a detectable signal to arrive at one or
multiple endpoint(s) that quantify or qualify the extent
of the perturbation. Bioassay is described by multiple
bioassay components: assay format, biology (biological
participants in various role and processes), design
method, physical detection method/technology,
screened entity, and endpoint. Bioassay includes one or
multiple measure groups to describe panel, profiling,
multiparametric (or multiplexed) assays (assays that
measure more than one effect of the perturbagen on
the system that is screened)”.
From these textual definitions, one might infer that
these two ontologies ostensibly covering the same domain
area have radically different conceptualisations of the con-
tent. This is also evidenced in their differing axiomatisa-
tion for the terms. As can be seen in Figure 3, OBI has
a smaller model using generic (not domain-specific) rela-
tionships such as ‘realizes’ and ‘has role’, while BAO has
a plethora of bioassay-specific relationships linking the
core assay entity to many different sorts of component
e.g. detection method, endpoint and measure group. On
the other hand, while BAO explicitly marks these seman-
tically distinct aspects with their own relationships and
hierarchies, OBI includes this information in the assay
classification hierarchy (e.g. ‘flow cytometry assay’ is a
type of assay). And indeed, OBI contains a significantly
larger number of different assay classes beneath their
‘assay’ entity than BAO does.
However, considering that both ontologies reflect the
same underlying processes (i.e. experiments), it is possible
to broadly synthesise their models, identifying appropri-
ate mappings between the classes and relationships used
in the two implementations. This integration is illustrated
in Figure 4.
The integration consists of the following mappings:
• Upper level: BAO does not present a standard
upper level classification, while OBI is classified
beneath BFO 1.1. Since eNanoMapper has adopted a
slim upper level drawn from a subset of BFO 2.0.,
we have mapped OBI’s ‘assay’ class to BFO’s ‘process’
in our subset, and furthermore mapped BAO’s
‘bioassay’ class to OBI’s ‘assay’ as a parent, bringing
both hierarchies into the same branch of the
ontology.
• Assay specification: OBI uses two constructs to
capture the design and objective of each assay: the
‘assay objective’ and the ‘plan specification’. BAO, on
the other hand, uses several different classes to
capture specific aspects of the design and objective of
the assay: the classes ‘physical detection method’,
‘assay design method’, ‘assay screening campaign
stage’, ‘assay format’, ‘bioassay specification’ and
‘endpoint’ all capture aspects of these areas. Thus,
we relate the OBI classes to those of BAO as
illustrated.
• Input: Assays typically have various subtances
containing e.g. molecular entities, proteins and so on
as participants. In OBI this is captured as a specified
input of a ‘material entity’ – i.e. very broad so as to
allow for all the possible different types of assay
beneath the same umbrella. In BAO, on the other
hand, the different types of input are listed
specifically as a ‘screened entity’, ‘molecular entity’ as
‘measured entity’ and ‘macromolecule’ as ‘target’.
Again, here we can subsume the BAO entities
beneath the OBI more broad axiomatization.
• Output: BAO captures the measured output of an
assay as a ‘measure group’, which in turn is a holder
for a table-like grouping of different outcomes or
measurements. OBI on the other hand captures
specifically that the specified output of an assay is an
‘information entity’. This can be tied together by
classifying BAO’s ‘measure group’ beneath the
generic IAO class ‘information content entity’.
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Figure 3 The axioms associated with the core ‘assay’ entity in OBI and ‘bioassay’ in BAO.
The PROV-O model for provenance of information is
also related to the assay models of BAO and OBI. At the
core level, prov’s ‘activity’ class broadly subsumes the OBI
‘assay’ class. PROV-O has an explicit representation of
‘agent’, which in the context of the assay can be taken to be
the scientist who is performing the experiment, which can
be represented in OBI and BAO at the level of the respon-
sible organisation. Another straightforward correspon-
dence is to the PROV-O’s ‘plan’ class, which is related to
the classes ‘plan specification’ and ‘bioassay specification’
Figure 4 Relating ‘assay’ from OBI with ‘bioassay’ from BAO. Entities from OBI are shown in grey while those from BAO are blue.
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in OBI and BAO respectively. Many of the relationships
included in PROV-O are useful for incorporating addi-
tional metadata about assays and the information entities
derived from them.
The challenge of conflicting definitions is well known
in the nanomaterial domain, with the community as a
whole struggling to come up with a definition for the
entities that are its focus. The NPO defines a nanoma-
terial as: “A chemical substance which has at least one
external dimension or internal structure or surface struc-
ture in the nanoscale size range”, and nanoparticle as:
“A primary particle which has an average size in the
nanoscale range; which has an identifiable and definite
chemical composition, property or function that uniquely
define the nanoparticle’s type as known; and, which may
or may not exhibit a size-intensive property”. NPO has
drawn on community standards for these definitions, and
given that NPO is the primary ontology for nanoma-
terial description, ideally we would like to adopt their
definitions. However, from an ontological perspective the
definitions could be said to show some confusion. Firstly,
it is not clear from these definitions alone what the dis-
tinction is between nanomaterial and nanoparticle. We
might assume that the nanomaterial is an aggregate con-
sisting of an arbitrarily large number of nanoparticles of
a given type (i.e. bulk granularity in the terminology of
[42]), and that the nanoscale size range referred to would
be the size of the components of the aggregate rather than
the material as a whole, which components are then the
nanoparticles. Given this assumption, it is perplexing that
the given nanoparticle definition refers to an average size,
when a single particle clearly cannot have an average size.
Secondly, strictly speaking, the final clause ‘may or may
not exhibit a size-intensive property’ adds no informa-
tion, however, from an understanding of the domain one
may gather that this clause is there because often nano-
materials do display size-specific properties, and that is
precisely why there is so much interest in them. Thus
this addendum might be better included as a comment. A
straightforward definition of nanomaterials might say that
they are materials containing structures in the approx-
imately 1-100 nm scale which exhibit novel properties
because of their small scale. The EU definition along these
lines removes the term “approximately”, in order to allow
its usage in a legal context, resulting in the following
definition of nanomaterial:
“A natural, incidental or manufactured material
containing particles, in an unbound state or as an
aggregate or as an agglomerate and where, for 50 % or
more of the particles in the number size distribution,
one or more external dimensions is in the size range 1
nm - 100 nm. In specific cases and where warranted by
concerns for the environment, health, safety or
competitiveness the number size distribution
threshold of 50 % may be replaced by a threshold
between 1 and 50 %” [43].
This definition has been criticised on scientific grounds
related to the potential limitation involved in defining
strict bounds for the size, distribution and agglomeration.
There has even been controversy about whether a defini-
tion for nanomaterials should be adopted at all, with [1]
arguing against on the grounds of heterogeneity in the
domain (e.g. different size ranges confer reactivity on dif-
ferent basic chemical structures), while [2] countering that
despite the heterogeneity, a definition that stands up to
legal scrutiny is essential in creating a regulatory environ-
ment that is able to protect the consumer from otherwise
invisible hazards (e.g. by enforced labelling for this class of
materials in consumer products). Leaving regulatory con-
siderations aside, on a practical level for the eNanoMap-
per project these classes should not remain undefined,
to comply with ontology best practices and in support of
data annotation: given the above similarity in definition
between NPO’s ‘nanomaterial’ and ‘nanoparticle’, it might
be difficult for data providers to decide which term to
use to annotate their data. It should also be noted that a
definition based only on the size of the individual com-
ponents of the aggregate material alone potentially also
includes many types of molecules that do fall within the
relevant size but which are not normally components of
nanomaterials. Here, the distinction between engineered
molecular entities and those which are naturally occurring
is relevant, but this distinction is not reflected in any of
the available definitions.
In order to address this definitional challenge within
eNanoMapper, we have explicitly differentiated the ‘nano-
material’ class from the ‘nanoparticle’ class by follow-
ing ChEBI’s distinction between ‘chemical substance’ and
‘molecular entity’. This means that we have defined a
material as some portion of a bulk aggregate substance,
and a particle as a single individual within such an aggre-
gate. This necessitates being careful to annotate particle
size distribution as a property of the material rather than
as a property of the particle.
Conclusion
We have presented the development and current struc-
ture of eNanoMapper, an ontology which draws heavily on
existing ontologies in order to provide a unified ontology
for the annotation of data about nanomaterial safety. Re-
use of ontology content in the development of new ontolo-
gies is not novel, and indeed is considered good practice
by ontology organisations such as the OBO Foundry [41].
However, the manual inclusion of content from third-
party ontologies is very difficult to maintain in the longer
term, even if the MIREOT approach is used [19]. We
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have thus presented a library to facilitate ontology re-use
through extracting subsets of existing ontologies accord-
ing to a small but versatile set of instructions, which
allows the resulting branches and components of different
ontologies to be automatically pieced together. The closest
existing tool for a similar application is the OntoFox tool
[44], which uses SPARQL to extract subsets from existing
ontologies, by default offering the OBO Foundry collec-
tion of ontologies as sources. Compared to OntoFox, our
solution offers no GUI or web service interface, but rather
is designed to run as a library in a fully automated pipeline.
Furthermore, OntoFox does not allow the specification
of new parents for the imported modules such that the
module fits into an integrated whole in a fully automated
fashion.
Since the domain of nanomaterial safety includes such
broad sub-domains as biological experiments, physico-
chemical and environmental characterization, and molec-
ular and biological entities, it would be an enormous
effort to redevelop such an ontology “from scratch”. Re-
use of already existing resources is not only less wasteful,
it is in fact the only way to ensure that the ontology
is able to be developed in the limited time frame avail-
able to the eNanoMapper project. The type of integration
which we have attempted is, however, uniquely challeng-
ing and involves both structural and conceptual synthesis
activities, which is particularly evident in the case of
the integration of the various assay classes from differ-
ent sources (BAO, OBI, NPO). We have presented our
first steps towards a comprehensive integration of all con-
tent relevant to this challenging domain, and described
both manual and automatically assembled content in the
eNanoMapper ontology.
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